Year: 2019

Mikko Pilkama nimitetty Heeros Oyj:n uudeksi toimitusjohtajaksi5.12.2019 13.50KTM Mikko Pilkama aloittaa Heeros Oyj:n toimitusjohtajana 1.1.2020.HEEROS OYJ Yhtiötiedote 5.12.2019 klo 13.50Heeros tiedotti 12.9. toimitusjohtajan vaihtumisesta.Mikko Pilkama on nimitetty Heeros Oyj:n toimitusjohtajaksi. Hän aloittaa Yhtiön palveluksessa 9.12.2019 ja toimitusjohtajan tehtävässä 1.1.2020. Nykyinen toimitusjohtaja Matti Lattu jatkaa  toimitusjohtajana 31.12.2019 asti ja yhtiön palveluksessa helmikuun loppuun asti.Pilkama on aikaisemmin toiminut merkittävissä johtotehtävissä useissa IT- ja finanssialan yrityksissä kuten Basware, CGI, Nets ja Luottokunta. Hän tuo Heerokseen rautaista osaamista SaaS-pohjaisen liiketoiminnan kannattavan ja kestävän kasvun rakentamisesta. Pilkama on 25-vuotisen työuransa aikana hankkinut kokemusta myös kansainvälisiltä...

Phase 2 study follows NYX-458 preclinical data demonstrating reversal of cognitive deficits in non-human primate model of Parkinson’s diseaseFourth Phase 2 study initiated by Aptinyx in 2019 across innovative CNS pipeline with data readouts expected over next 12 to 24 monthsEVANSTON, Ill., Dec. 05, 2019 (GLOBE NEWSWIRE) — Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the initiation of a Phase 2 clinical study of its novel NMDA receptor modulator, NYX-458, for the treatment of mild cognitive impairment associated with Parkinson’s disease. The company expects to report top-line data from the 135-patient Phase 2 study in the second half of 2021.“The initiation of this study marks an important milestone...

Further Strengthens Business Development Team with Key HirePARSIPPANY, N.J., Dec. 05, 2019 (GLOBE NEWSWIRE) — Interpace Bioscience’s subsidiary, Interpace Pharma Solutions today announced that it is continuing to expand a previously announced partnership agreement to jointly develop, promote and offer translational studies and clinical trial solutions to biotech and pharmaceutical companies with Genecast (Beijing) Biotechnology Co. Ltd (“Genecast”) of the Peoples Republic of China (PRC). Genecast is a leader in offering diagnostic products and services in the field of oncology and providing a wide range of diagnostic services to pharmaceutical and biotech companies in the PRC. Interpace is sending members of its technical/scientific and business development teams to China this week to begin the tech transfer requirements to support...

December 05, 2019 06:54 ET | Source: Danske InvestNasdaq CopenhagenNikolaj Plads 61007 København K   Parallelvej 172800 Kgs. LyngbyTelefon 33 33 71 71Telefax 33 15 71 71www,danskeinvest.dk   5. december 2019Forventede udbytter for 2019 for Investeringsforeningen Danske Invest De foreløbigt beregnede, men ureviderede udbytter inklusive udbetalt acontoudbytte fremgår af nedenstående skema.De endelige reviderede udbytter forventes godkendt den 4. februar 2020. Udbyttet fragår forventeligt i kursen på andelene den 5. februar 2020 og indgår forventeligt efter fradrag af en eventuel udbytteskat på investors konto den 10. februar 2020.Afdelinger ISIN-kode Samlet udbytte kr. pr. andel Heraf skattefrit udbytte kr. pr. andel Tidligere udbetaltaconto-udbyttekr. pr. andelDanmark, klasse DKK d DK0010252873 13,30 – –Danmark...

December 05, 2019 06:52 ET | Source: Danske Invest SelectNasdaq Copenhagen A/SNikolaj Plads 61007 København K   Parallelvej 172800 Kgs. LyngbyTelefon 33 33 71 71Telefax 33 15 71 71www,danskeinvest.dk   5. december 2019Forventede udbytter for 2019 for Investeringsforeningen Danske Invest Select De foreløbigt beregnede, men ureviderede udbytter inklusive udbetalt acontoudbytte fremgår af nedenstående skema. De endelige reviderede udbytter forventes godkendt den 4. februar 2020. Udbyttet fragår forventeligt i kursen på andelene den 5. februar 2020 og indgår forventeligt efter fradrag af en eventuel udbytteskat på investors konto den 10. februar 2020.Afdelinger ISIN-kode Samlet udbytte i kr. pr. andel  Heraf skattefrit udbytte kr. pr. andel Tidligere udbetaltaconto-udbyttekr. pr. andelEmerging Markets, klasse DKK d DK0016057474 2183,00 – –Euro...

44.95 g/t Gold over 5.6m and 10.66 g/t Gold over 11.2m in the Bonnefond intrusiveTORONTO, Dec. 05, 2019 (GLOBE NEWSWIRE) — QMX Gold Corporation (“QMX” or the “Company”) (TSX:V:QMX) is pleased to report the first results from its fall drilling campaign on the Bonnefond deposit (Figure 1). Bonnefond is located on the Val d’Or East Zone of QMX’s extensive land package in Val d’Or, Quebec (Figure 2). The fall Bonnefond drilling program is focused on both upgrading the intrusive inferred resource to the indicated resource category and drilling outside the intrusive in the higher-grade shear zones which is expected to improve definition and increase the grade and tonnage.Results to date have returned better than expected grades within the Bonnefond intrusive and support the predictiveness of our geological model in the shear zones to...

VANCOUVER, British Columbia, Dec. 05, 2019 (GLOBE NEWSWIRE) — Nanotech Security Corp. (TSXV: NTS) (OTCQX: NTSFF) (“Nanotech” or the “Company”), a leading innovator in the research, creation and production of nano-optic structures and colour-shifting materials used in authentication and brand enhancement, announces the Company will release financial results for its 2019 fourth quarter and year-end after the market closes on Thursday December 12, 2019. CEO Troy Bullock and CFO Monika Russell will host a conference call at 5:00 P.M. Eastern the same day. All interested parties are invited to participate in this conference call and should dial the numbers below approximately 15 minutes prior to the starting time.About NanotechNanotech researches, creates and produces nano-optic structures and colour-shifting materials used in authentication...

LAS VEGAS, NV, Dec. 05, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — CLS Holdings USA, Inc. (OTCQB: CLSH, CSE: CLSH) (“CLS” or the ”Company”), a diversified cannabis company operating as Cannabis Life Sciences, is pleased to announce that, through its 100% owned City Trees subsidiary, it has completed the buildout and licensing for phase 1 of its North Las Vegas processing facility.  The new, state-of-the-art extraction and production facility allows CLS to produce its own THC oil for use in all City Trees branded products.  CLS also expects to partner with 3rd party organizations interested in having their products manufactured at the newly licensed facility. The new manufacturing facility passed inspection with the North Las Vegas Fire Department for its phase 1 Hydrocarbon extraction and processing. This marks...

LOS ANGELES, Dec. 05, 2019 (GLOBE NEWSWIRE) — ChromaDex Corp. (NASDAQ:CDXC) announced today the expansion of its partnership with Matakana Health (MHL) until early 2023, which will now include Australia in its territory.  On Monday, ChromaDex announced the receipt of approval of nicotinamide riboside chloride (NR, or Niagen®) as an ingredient in listed Complementary Medicines from the Australian Therapeutic Goods Administration (TGA).MHL is an established dietary supplement manufacturer and distributor in New Zealand with national and Australian distribution in both online and offline channels. The company has more than 90 lines of organic and superfood products.“Matakana successfully launched Tru Niagen® in New Zealand in 2018,” says ChromaDex CEO Rob Fried. “We look forward to building on that momentum together as we expand into...